ArticleCureus2024

A Successful Switch From Ustekinumab to an Extended Dosing Interval of Guselkumab Without Induction in a Patient With Psoriasis Vulgaris.

Kazuki Yatsuzuka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.